Health

Wegovy Pill May Expand Access to Obesity Treatments

The United States Food and Drug Administration has greenlit the initial tablet form of a GLP-1 drug designed for shedding pounds, which might considerably broaden availability of obesity therapies. Produced by the Danish firm Novo Nordisk, this daily Wegovy pill is set to debut in early January, with clinical trial participants averaging a 16.6% drop in body weight.

Shotlee·January 2, 2026·Updated Jan 27, 2026·1 min read

The United States Food and Drug Administration has granted approval for the initial oral form of a GLP-1 medication intended for weight reduction, a step that could substantially broaden the reach of obesity therapies.

Produced by the Danish pharmaceutical company Novo Nordisk, the once-daily Wegovy tablet is slated to become available in early January. Novo Nordisk reports that individuals participating in clinical studies who used the Wegovy pill experienced an average loss of 16.6% in their total body weight.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Become aBeta Tester

Health tracking applications such as Shotlee can assist users in monitoring their progress during weight loss journeys when combined with these treatments.

Original source: Owensboro Messenger-Inquirer

View original article →

#Wegovy#obesity treatment#GLP-1 drug#FDA approval#weight loss#Novo Nordisk

Metabolic Health

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.

GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

Wegovy Pill May Expand Access to Obesity Treatments

📱 Get the Shotlee App

Related Articles

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

Wegovy Pill May Expand Access to Obesity Treatments

📱 Get the Shotlee App

Related Articles

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds